Johnson & Johnson announced significant positive updated and new data for Rybrevant (amivantamab) with lazertinib in first-line non-small cell lung cancer (NSCLC) at the American Society of Clinical Oncology (ASCO) meeting.
ASCO: Favorable Data For J&J Combo in 1L NSCLC Gain Attention
Positive new and updated data at ASCO for Rybrevant plus lazertinib could position the combo more strongly against Tagrisso in the first-line treatment of high-risk, EGFR-mutated non-small lung cancer.
